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Abstract 
Background: In French Guiana, doxycycline is used for both chemoprophylaxis and the treatment of malaria. The 
presence of isolates with reduced ex vivo susceptibility to doxycycline in French Guiana makes it critical to identify 
any genetic determinants contributing to the chemosusceptibility level of Plasmodium falciparum to doxycycline, 
such as pfmdt and pftetQ, which were recently identified as potential molecular markers in African isolates.
Methods: A Bayesian statistical approach was used to define different ex vivo doxycycline phenotypes. The pfmdt 
and pftetQ gene copy numbers were quantified by quantitative real-time polymerase chain reaction in 129 P. falcipa-
rum isolates collected between 2000 and 2010, and pftetQ, pfrps7, pfssurRNA, and pflsurRNA sequences were analysed 
after amplification by polymerase chain reaction.
Results: PftetQ and pfmdt copy numbers were not associated with reduced susceptibility to doxycycline in P. falci-
parum within French Guiana. Sequence analysis of the genes revealed five known single nucleotide polymorphisms. 
Three new SNPs were identified in the apicoplast ribosomal RNA long sub-unit (pflsurRNA): C740T, A1875C and 
A1875T. These polymorphisms were not associated with reduced chemosusceptibility to doxycycline.
Conclusions: The present study does not validate pfmdt and pftetQ genes as molecular markers of decreased sus-
ceptibility to doxycycline in P. falciparum isolates in French Guiana.
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Background
Malaria remains a public health problem in French 
Guiana despite measures to strengthen health protec-
tion and disease prevention. It occurs in geographi-
cal foci located along the rivers and near gold-mining 
sites in the Amazonian forest [1], where the high num-
ber of illegal foreign workers unfortunately limits the 
impact of preventive measures. Self-medication using 
imported molecules with an unclear compliance con-
tributes to the selection of drug-resistant parasites in 
the region [2]. Plasmodium falciparum accounts for 
30% of the 1,000 malaria cases reported each year by 
the health regional agency [3]. As in the neighbour-
ing countries of the Amazon basin, some strains of P. 
falciparum are resistant to chloroquine, amodiaquine, 
sulfadoxine–pyrimethamine, chloroquine–progua-
nil, halofantrine, and even quinine [4]. This justified 
the introduction of quinine–doxycycline combination 
therapy as a first-line treatment in 1995. It was replaced 
by the artemether–lumefantrine combination in 2002 
but is still used to treat severe malaria in second-line 
treatment. Doxycycline is an antibiotic of the tetracy-
cline family. Its anti-malarial activity has been known 
for 40  years following ex  vivo [5, 6] and clinical stud-
ies [7–9]. The mode of action of this antibiotic on the 
Plasmodium parasite is not fully understood. In bac-
teria, cyclines inhibit protein synthesis by binding to 
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protein S7 of the small ribosomal subunit and to vari-
ous ribonucleic acids of the 16S ribosomal RNA, pre-
venting the binding of aminoacyl-transfer RNA to site 
A of the ribosome and thus blocking the elongation 
step of translation [10]. In P. falciparum, the doxycyline 
mechanism of action targets two organelles, the mito-
chondria and the apicoplast. Cyclines also decrease the 
activity of an enzyme, dihydroorotate dehydrogenase, 
involved in the de novo synthesis of pyrimidines [11]. 
A related drug, minocycline, is also thought to decrease 
the transcription of mitochondrial genes (sub-unit I of 
cytochrome c oxidase and apocytochrome b) and plas-
tid genes (sub-unit rpoB/C of RNA polymerase) [12]. 
Doxycycline appears to principally target the apicoplast 
in P. falciparum, and may block translation by bind-
ing to the small ribosomal sub-unit, causing a delayed 
death [13]. Doxycycline given on a daily basis has been 
shown to be an effective causal chemoprophylaxis [14]. 
It is now recommended by the French health authori-
ties for chemoprophylaxis in countries with high preva-
lence of chloroquine resistance or multidrug resistance 
(group 3 countries), as in French Guiana [15]. French 
troops deployed in the illegal gold mines take 100  mg 
daily doses of doxycycline for prophylaxis. The ability 
of P. falciparum to rapidly develop resistance and the 
use of doxycycline for both chemoprophylaxis and the 
treatment of malaria in French Guiana impose a close 
monitoring of resistance to this drug. No clinical treat-
ment failure has been reported so far, but doxycycline 
is always used in combination for treatment. Although 
reported cases of malaria under doxycycline chemo-
prophylaxis are mostly believed to have resulted from 
poor compliance [16], they could also be explained by 
resistance. It is critical to identify early signs of resist-
ance before resistant strains become prevalent and 
compromise the clinical and prophylactic utility of the 
molecule. Indeed, Briolant et al. [17] identify an associ-
ation between the P. falciparum metabolite drug trans-
porter (pfmdt; PFE0825w) and P. falciparum GTPase 
TetQ (pftetQ; PFL171c) gene copy numbers, the pftetQ 
KYNNNN sequence polymorphism and a decreased 
ex  vivo susceptibility to doxycycline in African P. fal-
ciparum isolates. The threshold of decreased suscepti-
bility to doxycycline was established ex  vivo at 35  µM 
[18].
This study first aimed to determine the distribution and 
range of 50% inhibitory concentrations (IC50) of doxy-
cycline for 800 P. falciparum isolates assayed between 
2000 and 2010 in French Guiana. In the second part, 
the association between the pftetQ, pfmdt copy num-
bers sequence polymorphisms of the pftetQ, pfssurRNA, 
pflssurRNA, pfrps7 and with decreased susceptibility to 
doxycycline has been evaluated.
Methods
Plasmodium falciparum isolates
Between January 2000 and December 2010, 800 P. falci-
parum isolates were obtained from the different health 
centres of French Guiana and collected by the CNRCP 
(Centre National de Référence pour la Chimiosensibilité 
du Paludisme) hosted by the parasitology laboratory of 
the Institut Pasteur de la Guyane. Fifty per cent inhibi-
tory concentration (IC50) to doxycycline was determined 
using the ex vivo isotopic method described by Le Bras 
et  al. [19]. DNA was extracted from blood samples by 
QIAamp®DNA Blood (Qiagen) according to the manu-
facturer’s protocol.
Distribution and range of IC50
The statistical analysis was designed to answer the spe-
cific question of whether P. falciparum has a different 
profile of susceptibility to doxycycline. Parasite suscepti-
bility is expressed as the IC50. As a heterogeneous popu-
lation is observed, the data are assumed to come from a 
univariate Gaussian mixture with k components. Each 
observation is assumed to come from one of the k com-
ponents, and the label of the group from which each 
observation comes is unknown. The number of compo-
nents, the means, variances and weights of the differ-
ent components in the model are unknown, as well as 
the vector of allocations of the observations. The analy-
sis was performed in two steps. First, reversible jump 
Monte Carlo Markov Chains (RJMCMC) samplers were 
used to choose a suitable number of k components. The 
RJMCMC sampler is described by Richardson et al. [20]. 
The only difference with the algorithm is that we imple-
mented only birth and death moves, following Cappé 
et al.’s recommendations [21]. Once a relevant number of 
components had been chosen, standard Gibbs samplers 
were run to obtain estimates of the model parameters 
and classify the observations [22]. It is well known that 
these classical Markov Chain Monte Carlo techniques 
are not sufficient to cover all the parameter space; it can 
stay within a neighbourhood of a local mode and may fail 
to visit other important modes. In order to improve the 
exploration of the parameter space and thereby improve 
convergence, the RJMCMC and Gibbs samplers were 
embedded in a population-based algorithm. Because 
of the ‘label-switching’ problem caused by symmetry in 
the likelihood of the model parameters [23], the mixture 
components should be labelled before making inferences 
about the parameters. A classical ordering constraint was 
used, which is biologically relevant here. The algorithms 
were run for 50,000 burn-in iterations and 20,000 post-
burn-in iterations. These numbers are classically suffi-
cient to obtain reliable results. Moreover, each algorithm 
was run three times to check that results between two 
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different runs were similar and that there was no con-
vergence problem. This analysis was performed with R® 
software (version 2.10.1).
Quantification of the pfmdt and pftetQ gene copy numbers 
by TaqMan® real‑time PCR
TaqMan® real-time polymerase chain reaction (PCR) was 
performed using ABI7300 (Applied Biosystems) to esti-
mate the pfmdt (PFE08254w) and pftetQ (PFL1710c) gene 
copy numbers relative to the single-copy of pfβtubulin 
gene (PF10_0084) in 129 isolates from the different phe-
notypic subpopulations.
Primers and probes were used as describe by Briolant 
et  al. [17]. Individual PCR were performed using 1X 
TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 6  µM forward and reverse primers, 4  µM probe, 
and 1 µL of template DNA in a final volume of 25 µL. The 
thermal cycling conditions were 50°C for 2 min, 95°C for 
10 min, then 50 cycles of 95°C for 15 s and 60°C for 1 min 
for pfmdt, and 55°C for 10 s followed by 60°C for 1 min for 
pftetQ. Each sample was assayed in triplicate and analysed 
with SDS software (version 1.3; Applied Biosystems). The 
PCR efficiencies of all primers pairs were evaluated using 
a dilution series of P. falciparum 3D7 genomic DNA. The 
2−∆∆CT  method of relative quantification, where CT indi-
cates the threshold cycle, was used to estimate the copy 
numbers of pfmdt and pftetQ genes with the formula 
∆∆CT =
(









 [24]. Genomic DNA extracted from 
P. falciparum 3D7, which has a single copy of each gene, 
was used for calibration, whereas pfβtubulin served as 
the control housekeeping gene in all experiments. Data 
were analysed using Epi info® software (version 3.5.1). 
Differences in the pfmdt and pftetQ gene copy numbers 
between the phenotypic groups were tested using the 
Kruskal–Wallis test. Genotype proportions were com-
pared using the Fisher exact test. Statistical significance 
was denoted by p ≤ 0.05.
Gene sequence polymorphism analysis
Four genes, pftetQ, pfssurRNA, pflsurRNA and pfrps7, 
were amplified by PCR with oligonucleotide primer 
pairs designed using Primer 3® software (version 0.4.0) 
(Table  1). As there was only a few isolates with an IC50 
exceeding the threshold, it was initially chosen to 
sequence genes from only ten isolates with the highest 
IC50 [median 40.15 µM (min 29.82 µM; max 77.84 µM)] 
and ten isolates with low IC50 to doxycycline [median 
4.83 µM (min 3.28; max 6.05)]. The reaction mixture con-
sisted of 10× mix PCR Gold buffer®, 200 µM of dNTPs, 
variable concentration of MgCl2 (Table  1), 200  nM of 
forward and reverse primers, 4  UI/100  µL of Ampli 
Taq Gold DNA polymerase (Applied Biosystems) and 
2 µL of DNA in a final volume of 50 µL. Thermal Mas-
tercycler® (Eppendorf ) were programmed as follows: 
94°C for 10 min then 35 cycles alternating 94°C for 30 s, 
hybridization temperature (Table 1) for 30 s and 72°C for 
extension at 1  min per 1,000  bp, followed by a 15-min 
final extension step at 72°C. The reaction products 
were sequenced by Millegen® biotechnologies (Labège, 
France). Sequences were analysed using MEGA® soft-
ware (version 5.05). Epi Info® software (version 3.5.1) 
was used to perform data analysis. Differences in DNA 
sequences (pfssurRNA, pflsurRNA, pfrps7, pftetQ) and in 
amino acid sequences [PfTetQ, PfRps7—itals—as before 
? (No because is official nomenclature)] between the two 
groups were tested using the Kruskal–Wallis test.
Results
Distribution and range of IC50 in 800 isolates between 2000 
and 2010
Three runs of RJMCMC algorithms were performed, gen-
erating three chains of interest. All of these chains gave 
similar results for the number of components. Table  2 
describes the mean values for the estimated posterior 
probabilities of the number of components in these three 
runs. The posterior distribution favoured four compo-
nents, as the probability of k = 4 was the highest. Three 
runs of Gibbs sampler were performed and gave very 
similar results (Table 3). Figure 1 shows that the posterior 
Gaussian mixture fits quite well with the observed IC50 
density.
Table 1 Forward and  reverse primers, hybridization tem-
perature and  MgCL2 concentration used for  polymerase 
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The pfmdt and pftetQ gene copy numbers
From 800 samples, 129 isolates were selected within 
the four phenotypic groups: 58 isolates [IC50 median 
4.09  µM (min 0.7; max 11.1)] from group 1, 43 isolates 
[IC50 median 13.7 µM (min 11.2; max 21.96)] from group 
2, 23 isolates [IC50 median 26.5 µM (min 22.2; max 37)] 
from group 3, and five isolates [IC50 median 50.92  µM 
(min 44.5; max 77.84)] from group 4. Only seven iso-
lates had two or more copies of the pftetQ gene, showing 
no association with the phenotypic groups (Fisher test, 
p > 0.05). Among these isolates, five presented very low 
IC50 to doxycycline (group 1), and two presented high 
IC50 (group 3). Two copies of the pfmdt gene were found 
in only one group 3 isolate, with an IC50 of 35.8 µM. No 
statistical association was observed between the presence 
of multiple copies of pfmdt or pftetQ genes and a higher 
IC50 or belonging to phenotypic group 3 or 4.
Gene sequence polymorphism
Sequence analysis of the four genes in ten isolates with 
high IC50 and 10 isolates with low IC50 revealed new 
single-nucleotide polymorphisms (SNPs) in the gene 
sequence of the long sub-unit ribosomal RNA (pflsur-
RNA), namely C740T (Genbank accession number: 
KM272854), A1875C (Genbank accession number: 
KM272855) and A1875T (Genbank accession number: 
KM272856). These SNPs were not previously noted in 
the PlasmoDB SNP database [25]. They were found in 
35, 20 and 30% of isolates, respectively. Other SNPs were 
observed in the pftetQ and pfssurRNA genes, but neither 
they nor PfTetQ KYNNNN sequence polymorphism 
were significantly associated with the doxycycline IC50 
phenotypes. No mutation was observed in pfrps7.
Discussion
Doxycycline belongs to the tetracycline family of anti-
biotics. Tetracyclines are an effective anti-malarial, but 
their mechanism of action is much less clearly defined 
for Plasmodium than for bacteria. Ex vivo, doxycycline 
specifically impaired the expression of apicoplast genes 
and blocked apicoplast genome replication, leading to the 
loss of apicoplast function in the progeny of treated para-
sites and delayed death [13]. Most prophylactic failures 
of doxycycline against P. falciparum are associated with 
poor compliance [26] or inadequate low doses [27]. Dox-
ycycline pharmacokinetic parameters could explain some 
Table 2 Estimated posterior probabilities of the number of components obtained on three runs
k = 1 k = 2 k = 3 k = 4 k = 5 k = 6 k = 7 k = 8 k = 9 k = 10
0.00 0.00 0.00 0.42 0.32 0.15 0.07 0.03 0.01 0.00
Table 3 Parameters of  the Gaussian mixture with  four 
components for the three runs
µ means, σ standard deviation, w weights of each components, n number of 
observation for each components, β β parameter.
run1 run2 run3 Mean
µ
 µ1 7.46 7.44 7.42 7.44
 µ2 13.89 13.76 13.77 13.81
 µ3 24.12 23.69 23.77 23.86
 µ4 54.49 53.94 53.98 54.14
σ
 σ1 6.72 6.66 6.61 6.66
 σ2 16.00 15.95 15.97 15.97
 σ3 39.91 39.47 39.30 39.56
 σ4 158.50 161.31 162.94 160.92
w
 w1 0.5439 0.5367 0.5358 0.5388
 w2 0.3818 0.3816 0.3859 0.3831
 w3 0.0633 0.0704 0.0672 0.0670
 w4 0.0108 0.0112 0.0109 0.0110
n
 n1 481 477 480 479
 n2 281 285 282 283
 n3 32 32 32 32
 n4 6 6 6 6
β 46.06 45.89 45.80 45.9
Figure 1 Distribution and density of the observed IC50, posterior 
components and sum of components.
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of these cases, given its short elimination half-life (16 h) 
for slow action and delayed anti-malarial effect [28]. The 
early detection of reduced susceptibility or resistance 
to doxycycline entailed the monitoring of chemosus-
ceptibility. A Bayesian mixture modelling approach was 
adopted to study doxycyline susceptibility phenotypes 
in the isolates circulating in French Guiana. All 800 IC50 
values were classified into four components. All the iso-
lates from group 4 and two isolates from group 3 had an 
IC50 value above the decreased susceptibility threshold 
of 35 µM [18]. This represents 1% of isolates. These data 
are consistent with clinical observations of limited pro-
phylactic failures when doxycycline is used according to 
recommendations. Genotyping analysis was then neces-
sary to try to identify the molecular basis of the suscep-
tibility differences and correlate genetic profiles to the 
phenotypes.
Three potential molecular markers of decreased sus-
ceptibility were identified in African isolates, namely 
copy number variations of the pfmdt and pftetQ gene 
and PfTetQ KYNNNN sequence polymorphism [17]. 
These variations were also associated with decreased 
ex  vivo susceptibility to doxycycline in isolates from 
the National Reference Centre for Imported Malaria 
in France mainland [29]. PfTetQ protein belongs to the 
translation elongation factor GTPase family, and pos-
sesses a plastid signal peptide [30]. It shares sequence 
similarity with several other bacterial resistance proteins 
[31]. Although the results showed find multiple copies 
of pftetQ gene in seven isolates, five of these had a very 
low IC50. It therefore follows that this genetic determi-
nant is not associated with a decreased susceptibility 
to doxycycline in French Guiana and cannot be used to 
monitor doxycycline susceptibility. The protein product 
of the pfmdt gene corresponds to a putative metabolic 
drug transporter of the plasma membrane, and shows a 
similar sequence to the tetracycline resistance protein 
PfTetA, an efflux pump involved in bacterial resistance 
[32]. It was hypothesized that variations in the copy num-
ber of pfmdt gene can produce multiple efflux pumps and 
mediate resistance by increasing transport of doxycycline 
out of the cell. Previous research has demonstrated that 
an increased copy number of the P. falciparum multid-
rug resistant 1 (pfmdr1; PFE1150w) gene, which encodes 
an efflux pump of the vacuolar digestive membrane, is 
associated with mefloquine resistance in P. falciparum 
isolates from Southeast Asia [33]. Two copies of the 
pfmdt gene were found in just one isolate, with an IC50 of 
35.8 µM. The other nine isolates which IC50 values corre-
sponded to a decreased doxycycline susceptibility did not 
present multiple copies of pfmdt. This gene could there-
fore be involved in decreased doxycycline susceptibility 
but cannot be the only factor involved. Finally, PfTetQ 
KYNNNN sequence polymorphism was not associated 
with doxycycline IC50 phenotypes. A recent study on 
Kenyan isolates found a correlation between this poly-
morphism and a decreased susceptibility to doxycycline 
but not for pfmdt and pftetQ gene copy numbers. Sur-
prisingly, multiple pftetQ gene copy numbers were asso-
ciated with very low IC50 [34]. Further studies in other 
endemic regions are needed to test the reliability of these 
molecular polymorphisms as markers for decreased dox-
ycyline susceptibility.
In this study, the results did shown observe any muta-
tion in the pfrps7 and pfssurRNA genes, although S7 and 
the small sub-unit ribosomal RNA are molecular targets 
of tetracyclines in bacteria [35, 36]. Three new SNPs were 
found in the DNA sequence of pflsurRNA, but with-
out any association with a decreased susceptibility to 
doxycycline.
Conclusions
Doxycycline is currently the only anti-malarial drug for 
which no P. falciparum treatment failure has been doc-
umented. The distribution of ex  vivo susceptibility to 
doxycycline in French Guiana divided the population in 
four phenotypic groups. Only 1% of the 800 tested iso-
lates had reduced susceptibility to doxycycline ex  vivo, 
consistent with clinical observations. The present study 
does not validate the pfmdt and pftetQ gene as molecular 
markers of decreased susceptibility to doxycycline in P. 
falciparum French Guiana isolates.
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